Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 21
States / cities: Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more

Conditions: Pulmonary Arterial Hypertension
Interventions: MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Graves' Disease
Interventions: Levothyroxine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pediatric Obesity
Interventions: Lifestyle intervention and carotenoid supplements, Lifestyle intervention and placebo; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 8 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: PANCRECARB® (pancrelipase), Placebo; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Muscular Dystrophies
Interventions: GSK3439171A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Congestive Heart Failure
Interventions: Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: EDP1815; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 19 more

Conditions: Alzheimer's Disease
Interventions: Resveratrol, Placebo; Drug
Lead sponsor: Alzheimer's Disease Cooperative Study (ADCS); Other
Eligibility: 50 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more

Conditions: Intradialytic Hypotension
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Medford, Oregon

Conditions: Von Hippel-Lindau Syndrome
Interventions: Dovitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastroesophageal Reflux
Interventions: VECAM 40/300, Esomeprazole 20 mg; Drug
Lead sponsor: Vecta Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: San Diego, California • Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 Capsule; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Schizophrenia, Schizophrenia; Psychosis
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more

Conditions: Migraine Headaches
Interventions: Theramine (medical food/old drug), Placebo (l-alanine); Drug · Other
Lead sponsor: Vincent Martin, MD; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Uterine Fibroids
Interventions: telepristone acetate 12 mg, telepristone acetate 3 mg, telepristone acetate 6 mg, telepristone acetate 24 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Miami Gardens, Florida • Houston, Texas

Conditions: Gastroesophageal Reflux
Interventions: Omeprazole, Vecam; Drug
Lead sponsor: Vecta Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Long QT Syndrome, Abnormalities, Drug-Induced
Interventions: Progesterone, Ibutilide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Infertility, Female
Interventions: Ibuprofen 800 mg oral, Ketorolac 30mg oral; Drug
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Schizophrenia
Interventions: Minocycline, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Gut Microbiome, Skin Microbiome, Gut Lipidome, Skin Lipidome, Blood Lipidome
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Smith-Magenis Syndrome, Circadian
Interventions: tasimelteon, placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 3 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Santa Monica, California • Baltimore, Maryland • Chevy Chase, Maryland + 1 more

Conditions: Pharmacokinetics
Interventions: TAK-875 and Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

Early Levothyroxine Post Radioactive Iodine

Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Resveratrol for Alzheimer's Disease

Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

A Study of LY4065967 in Healthy Participants

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

Theramine® in the Prevention of Migraine Headache

Extension of Study ZPV-200

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Ibuprofen Versus Ketorolac for Pain Relief During Hysterosalpingogram

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

The Influence of Oral Probiotics on the Microbiome and Lipidome

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

TAK-875 Glimepiride Drug-Interaction Study